全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...
-  2016 

2型糖尿病合并毛霉菌病的临床分析
Clinical analysis of type 2 diabetes mellitus-associated mucormycosis

DOI: 10.7652/jdyxb201605018

Keywords: 毛霉菌病,2型糖尿病,临床特点,治疗
mucormycosis
,type 2 diabetes mellitus,clinical characteristic,treatment

Full-Text   Cite this paper   Add to My Lib

Abstract:

摘要:目的 分析2型糖尿病合并毛霉菌病的临床特点和预后并结合国内外相关文献报道,进一步加深对疾病的认识并提高早期诊断水平。方法 回顾性分析6例2型糖尿病合并毛霉菌病患者的临床资料。结果 6例患者中,分别为随机血糖>13mmol/L(6/6)、发热(6/6)、酮症(6/6)、白细胞升高(6/6)、酸中毒(5/6),头颅核磁共振(MRI)和胸部计算机断层扫描(CT)无特征性表现,真菌涂片阳性(3/6),病理活检阳性(5/6),早期应用两性霉素B配合局部清创、手术治疗治愈率(5/6)。结论 2型糖尿病合并毛霉菌病的诊断要点为随机血糖>13mmol/L、糖化血红蛋白>10%、酸中毒、白细胞升高及进行局部组织病理活检。早期足量应用两性霉素B和进行局部病变的手术治疗是治愈的关键。
ABSTRACT: Objective To analyze the clinical characteristics and progress of patients with type 2 diabetes mellitus-associated mucormycosis and to gain a better understanding of the disease by literature review. Methods A retrospective analysis was conducted in 6 patients treated for type 2 diabetes mellitus-associated mucormycosis. Results Six cases in our hospital had clinical data of type 2 diabetes mellitus-associated mucormycosis. We found random blood glucose >13mmol/L (6/6), fever (6/6), ketoacidosis (6/6), elevated leukocytes count (6/6), acidosis (5/6), positive fungal smear (3/6), positive pathological biopsy (5/6), and no skull MRI or chest CT characteristic manifestation. All the patients were treated with amphotericin B and surgical treatment, with the curative rate of 5/6. Conclusion Type 2 diabetes mellitus-associated mucormycosis is characterized by tendency for random blood glucose >13mmol/L, glycosylated hemoglobin>10%, ketoacidosis, acidosis, elevated leukocytes count, and pathological biopsy. Early and sufficient amount of liposomal amphotericin B and surgical treatment on local lesion are the key to treatment

References

[1]  R?aPING MJ, HEINZ WJ, KINDO AJ, et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry[J]. Antimicrob Chemother, 2010, 65(2):296-302.
[2]  SKIADA A, PAGANO L, GROLL A, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007[J]. Clin Microbiol Infect, 2011, 7(12):1859-1867.
[3]  MEAS T, MOULY S, KANIA R, et al. Zygomycosis: an uncommon cause for peripheral facial palsy in diabetes[J]. Diabetes Metab, 2007, 33(3):227-229.
[4]  HOT A, MAUNOURY C, POIREE S, et al. Diagnostic contribution of positron emission tomography with [18F] fluorodeoxyglucose for invasive fungal infections[J].Clin Microbiol Infect, 2011, 17(3):409-417.
[5]  TERBLANCHE M, ALMOG Y, ROSENSON RS, et al. Statins and sepsis: multiple modifications at multiple levels[J]. Lancet Infect Dis, 2007, 7(5):358-368.
[6]  TLEYJEH IM, KASHOUR T, HAKIM FA, et al. Statins for the prevention and treatment of infections: a systematic review and meta-analysis[J]. Arch Intern Med, 2009, 169(18):1658-1667
[7]  CHAMILOS G, LEWIS RE, KONTOYIANNIS DP. Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole[J]. Antimicrob Agents Chemother, 2006, 50(1):96-103.
[8]  SPELLBERG B, EDWARDS J JR, IBRAHIM A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management[J]. Clin Microbiol Rev, 2005, 18(3):556-569.
[9]  张学辉,黄健男,廖志群. 鼻眶脑型毛霉菌病――附2例报告及文献复习[J]. 罕少疾病杂志, 2005, 1(12):7-8.
[10]  TURUNC T, DEMIROGLU YZ, ALISKAN H, et al. Eleven cases of mucormycosis with atypical clinical manifestations in diabetic patients[J]. Diabetes Res Clin Pract, 2008, 82(2):203-208.
[11]  SUN HY, SINGH N. Mucormycosis: its contemporary face and management strategies[J]. Lancet Infect Dis, 2011, 11(4):301-311.
[12]  SAFDER S, CARPENTER JS, ROBERTS TD, et al. The ??Black Turbinate?? sign: An early MR imaging finding of nasal mucormycosis[J]. AJNR Am J Neuroradiol, 2010, 31(4):771-774.
[13]  BEN-AMI R, LEWIS RE, TARRAND J, et al. Antifungal activity of colistin against mucorales species in vitro and in a murine model of Rhizopus oryzae pulmonary infection[J]. Antimicrob Agents Chemother, 2010, 54(1):484-490.
[14]  LANTERNIER F, DANNAOUI E, MORIZOT G, et al. French Mycosis Study Group. A global analysis of mucormycosis in France: the RetroZygo? Study (2005-2007)[J]. Clin Infect Dis, 2012, Suppl 1:35-43.
[15]  YANG W, LU J, WENG J, et al. China National Diabetes and Metabolic Disorders Study Group. Prevalence of diabetes among men and women in China[J]. N Engl J Med, 2010 25, 362(12):1090-1101.
[16]  MANTADAKIS E, SAMONIS G. Clinical presentation of zygomycosis[J]. Clin Microbiol Infect, 2009, 15, Suppl 5:15-20.
[17]  SINGH NP, GARG S, KUMAR S, et al. Multiple cranial nerve palsies associated with type 2 diabetes mellitus[J]. Singapore Med J, 2006, 47(8):712-715.
[18]  GALGOCZY L, PAPP T, LUKACS G, et al. Interactions between statins and Penicillium chrysogenum antifungal protein (PAF) to inhibit the germination of sporangiospores of different sensitive zygomycetes[J]. FEMS Microbiol Lett, 2007, 270(1):109-115.
[19]  TERBLANCHE M, ALMOG Y, ROSENSON RS, et al.Statins and sepsis: multiple modifi cations at multiple levels[J]. Lancet Infect Dis, 2007, 7(5):358-368.
[20]  BROADY R, LEVINGS MK. Graft-versus-host disease: suppression by statins[J]. Nat Med, 2008, 14(11):1155-1156.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133